Skip to content
Review Open access

Machine learning approaches for cancer prognosis and diagnosis via non-coding RNA: a comprehensive review

Sep 2026 · Briefings in Bioinformatics · Vol 27 · 0 citations · 81 references
Medicine

TL;DR

This review critically evaluates ML-driven frameworks for cancer diagnosis and prognosis across four ncRNA subclasses, namely miRNAs, lncRNAs, circRNAs, and piRNAs, while also acknowledging the biophysical and thermodynamic models that reinforce ncRNA bioinformatics.

Abstract

Abstract Non-coding RNAs (ncRNAs), once considered genomic dark matter, are now established as key regulators of gene expression with widespread roles in cellular homeostasis and disease. In cancer, ncRNA expression is frequently and systematically dysregulated, and many of these molecules circulate in stable, protected form within biofluids, offering a compelling basis for non-invasive or minimally invasive diagnostic strategies. However, their clinical translation remains substantially hindered to date due to biological complexity, technical noise, and high dimensionality inherent to ncRNA expression datasets. In this context, machine learning (ML) has emerged as a powerful analytical tool to address these challenges, enabling the identification of subtle, reproducible ncRNA signatures predictive of diverse malignancies. This review critically evaluates ML-driven frameworks for cancer diagnosis and prognosis across four ncRNA subclasses, namely miRNAs, lncRNAs, circRNAs, and piRNAs, while also acknowledging the biophysical and thermodynamic models that reinforce ncRNA bioinformatics. Despite substantial methodological progress in ML-based cancer diagnosis and prognosis, key challenges persist, including tumor biological heterogeneity, limited multicenter validation, and the lack of widely adopted standardized protocols for preprocessing, normalization, and reporting workflows. Furthermore, many current ML models lack interpretability in biological or clinical context, constraining their translational utility. By synthesizing recent advances and identifying unresolved barriers, this review charts a roadmap for developing a robust, clinically actionable ncRNA biomarker platform for cancer detection. With global cancer incidence projected to exceed 35 million annual cases by 2050, validated ncRNA-ML-driven frameworks hold potential to revolutionize early-stage detection and personalized therapeutic strategies, thereby reducing the escalating socio-economic burden of cancer worldwide.

Read PDF

Similar papers

2026

Large Language Models for Non-Coding RNA Biomarker Discovery in Breast Cancer.

This chapter explores the integration of LLMs with ncRNA biology, focusing on circRNAs, snoRNAs, and piRNAs in BC, and proposes a computational framework for biomarker identification.

Tamizhini Loganathan · 0 citations
2026

A Comprehensive Pipeline for Long Non-Coding RNA Discovery and Characterization in Cancer.

It is proposed that the upregulated lncRNA ENSG00000265613 may enhance malignancy by stabilizing the RNA target ENSG00000582008 in luminal A breast cancer, particularly given its established role in oncogenesis.

C. Guda, Sankarasubramanian Jagadesan, Avinash M. Veerappa · 0 citations
Review Open access Oct 2026

Uncovering the Role of Small and Intermediate-Length Non-Coding RNAs in Glioma Pathogenesis and Prognosis

Gliomas are the most prevalent and aggressive primary tumors of the central nervous system (CNS), with glioblastoma demonstrating particularly poor survival rates despite multimodal treatment approaches. The extensive molecular heterogeneity and resistance to conventional therapies highlight the urgent need for novel b...

J. Machhi, Priya U. Kumthekar, Stella Hartmann · 0 citations
Review Open access Oct 2026

Exploring non-coding RNAs in Prostate Cancer: from Biomarkers to Therapeutic Strategies

Prostate cancer (PCa) is the second most prevalent malignancy and a leading cause of can- cer-related mortality in males worldwide. Despite advancements in therapeutic strategies, such as radical prostatectomy, radiotherapy, androgen deprivation therapy (ADT), and chemotherapy, treatment outcomes for metastatic castrat...

Dharanidharan Dhanabalan, N. Shanmugam · 0 citations
Review Aug 2026

The regulatory role of non-coding RNAs in taxane resistance of breast cancer.

Targeting ncRNAs via various therapeutic approaches, including herbal compounds and synthetic peptides, has shown hopeful findings in reversing taxane resistance in breast cancer, highlighting a promising avenue for the management of taxane resistance in breast cancer.

Cui-Cui Sun, Lingling Lv, Qinzheng Xu et al. · 0 citations
Review Open access Aug 2026

A multi-layer framework for computational cancer epigenomics

A structured multi-layer interpretation framework is proposed that links computational outputs across data-level processing, epigenomics-informed integrative regulatory modeling, and multi-omics-informed clinical interpretation, enabling traceable and mechanistically interpretable clinical inference.

M. Srivastava, Pratik Kumar, Ankita Chouhan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.